CellSource Co (4880.T) Stock Price

CellSource Co Price

JPX·CLOSED
303.00
​
Market closed

Over the last 8 years CellSource Co grew revenue by 27.9% annually, reaching 3.71 B JPY. Earnings per share have declined at 25.4% per year over the last 8 years. For CellSource Co, the net margin of 0.3% is down versus 22.3% a few years ago. At today's price the dividend yield works out to roughly 1.65%. The payout ratio is around 930% of earnings. The consensus 12-month price target for CellSource Co is 897.60 JPY, about 196.2% above where the stock trades today. Of 7 analysts, 0 rate the stock a buy — an overall Sell consensus.

CellSource Co stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

CellSource Co business model & stock analysis

CellSource Co., Ltd. generates revenue through its Regenerative Medicine Related business segment, which provides contracted services for processing tissues and cells from fat and blood to medical institutions, along with support services for regenerative medicine laws and regulations related to safety assurance. The company also sells medical equipment within this segment. The Consumer business segment focuses on selling cosmetics and facial products directly to general consumers. Both segments operate under the company's brand without additional brand names mentioned in the description. The Regenerative Medicine Related business segment targets medical institutions and regulatory compliance support for regenerative medicine safety, while the Consumer business segment serves general consumers seeking cosmetics and facial care products. The company's products include processed tissue and cell services, regulatory support, medical equipment, and consumer skincare items, all sold under the CellSource brand. CellSource Co., Ltd. employs 109 full-time employees to manage its two business segments, with the Regenerative Medicine Related segment handling medical services and equipment sales, and the Consumer segment focusing on direct-to-consumer product sales. The company's revenue streams are derived from these two distinct operational areas without any additional external partnerships or third-party brands.

Frequently asked questions about CellSource Co

Analysts currently set an average price target of 897.60 JPY for the CellSource Co stock (median: 897.60 JPY), implying +192.4 % versus the latest price. The consensus is based on 7 analyst ratings.

7 analysts currently rate the CellSource Co stock: 0 recommend buying, 3 holding and 4 selling. For 2026, analysts expect CellSource Co to generate revenue of 3.37 B JPY and earnings per share of -5.00 JPY.

Converted at the current exchange rate, the CellSource Co share trades at 1.72 EUR (303.00 JPY).

The CellSource Co share (4880.T) is listed on 1 stock exchanges, including: Tokio (JPX) (4880.T).

The expected revenue of CellSource Co is 3.37 B JPY. This figure is based on current financial data and reflects the company's business performance.

The expected profit of CellSource Co is -99.15 M JPY. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of CellSource Co is currently -60.57. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the CellSource Co stock.

The price-to-sales ratio (P/S) of CellSource Co is currently 1.78. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the CellSource Co stock.

The Eulerpool Quality Score for CellSource Co is 1/10.

The ISIN of CellSource Co is JP3423580004. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of CellSource Co is 4880.T. The ticker symbol is used to trade CellSource Co shares on the stock exchange.

Fair ValueTerminal
312.09 JPY
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Life Sciences Tools & Services
Number of shares
Employees
Revenue per Employee
34.04 M JPY
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
Currency
JPY
Initial public offering
Oct 28, 2019
ISIN
JP3423580004
Cusip
J0561V102
Market capitalization
6.01 B JPYMid Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2026
-60.57
P/Ee 2027
75.75
P/Ee 2028
25.04
P/Ee 2029
—
P/S
P/Se
1.78
EV/EBIT
—
P/B Ratio
1.00
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
0.18 %
Dividend
Dividend yield
1.65 %
Est. Dividend Yield
3.30 %
Payout Ratio
929.70 %
Dividend growth Ø5Y
—
Dividend payments per year
1
Dividend paid since
3 years
Dividend not reduced since
1 year
Dividend increased since
0 years
Dividend withholding tax
15.32 %
Last updated Oct 27, 2026, 8:20 AM

CellSource Co Peer Group

CellSource Co Ticker

JPX · 4880.T

CellSource Co FIGI

4880:JP · BBG00Q9X56R24880:JT · BBG00Q9X6X654880:JJ · BBG00Q9X6XH34880:JE · BBG00Q9X6XL84880:JI · BBG00Q9X6XM74880:JU · BBG00Q9X6XN64880:JW · BBG00Q9X6XP44880:JV · BBG0193RDLM1

All fundamentals and in-depth analysis of CellSource Co

Our stock analysis for CellSource Co stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of CellSource Co. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.